OverviewSuggest Edit

NovoCure engages in the development, manufacture and commercialization of tumor treating fields for the treatment of solid tumors. The Company markets its proprietary therapy, TTFields delivery system, for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

TypePublic
Founded2000
HQSaint Helier, JE
Websitenovocure.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2019)782(+31%)
Job Openings47
Revenue (FY, 2019)$351.3 M(+42%)
Share Price (Sept 2020)$105.9 (+2%)
Cybersecurity ratingAMore

Key People/Management at NovoCure

William F. Doyle

William F. Doyle

Executive Chairman
Asaf Danziger

Asaf Danziger

Chief Executive Officer, Director
William Burkoth

William Burkoth

Director
Mike Ambrogi

Mike Ambrogi

Chief Operating Officer
Yoram Palti

Yoram Palti

Founder
Louis Lavigne

Louis Lavigne

Director
Show more

NovoCure Office Locations

NovoCure has offices in Saint Helier, Atlanta, Boston, Charlotte and in 33 other locations
Saint Helier, JE (HQ)
13 Grenville St
München, DE
Elektrastraße 6
Chiyoda City, JP
Gran Tokyo North Tower, 36th floor, 1-chōme-9-1 Marunouchi
Root D, CH
D4 Pk. 6
Atlanta, US
Atlanta, GA, USA
Boston, US
Boston, MA, USA
Show all (38)

NovoCure Financials and Metrics

NovoCure Revenue

Embed Graph
View revenue for all periods
NovoCure's revenue was reported to be $351.32 m in FY, 2019
USD

Revenue (Q2, 2020)

115.9m

Gross profit (Q2, 2020)

90.5m

Gross profit margin (Q2, 2020), %

78%

Net income (Q2, 2020)

1.7m

EBIT (Q2, 2020)

6.7m

Market capitalization (23-Sept-2020)

10.7b

Closing stock price (23-Sept-2020)

105.9

Cash (30-Jun-2020)

196.8m

EV

10.7b
NovoCure's current market capitalization is $10.7 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

33.1m82.9m177.0m248.1m351.3m

Cost of goods sold

20.6m39.9m55.6m80.0m88.6m

Gross profit

12.5m43.0m121.4m168.0m262.7m

Gross profit Margin, %

38%52%69%68%75%
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

9.0m13.1m17.9m21.7m34.9m38.4m50.1m52.1m61.5m64.8m73.3m86.7m92.1m101.8m115.9m

Cost of goods sold

5.7m8.0m9.8m11.1m11.7m13.2m15.2m18.2m19.8m18.9m19.8m21.1m22.9m24.5m25.5m

Gross profit

3.3m5.1m8.1m10.6m23.2m25.2m35.0m33.9m41.7m45.8m53.5m65.6m69.2m77.3m90.5m

Gross profit Margin, %

37%39%45%49%67%66%70%65%68%71%73%76%75%76%78%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(111.6m)(131.8m)(61.7m)(63.6m)(7.2m)

Depreciation and Amortization

3.2m5.7m7.7m9.0m8.5m

Inventories

(10.1m)(12.0m)3.5m(529.0k)(1.2m)

Accounts Payable

7.0m1.6m(1.1m)9.5m16.9m
USDQ3, 2015

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.4 x
Show all financial metrics

NovoCure Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

NovoCure Online and Social Media Presence

Embed Graph

NovoCure News and Updates

Acadia, Novocure & Alexion Stocks Are Out Of Favor, But Promising

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -9% year-to-date versus the S&P 500 which is up by about 7.9% over the same period. The theme remains up by about 45% since the end of 2017, versus 31% for the S&P 500. While Alexion Pharmaceuticals is down the least...

Alexion, Novocure, ACADIA: Out Of Favor Health Care Stocks Poised For Gains

The performance of the healthcare sector has been mixed this year. While dental and surgery-related stocks have declined - as Covid-19 impacts sectors that require a close person to person contact, companies working on Covid-19 vaccines have outperformed significantly...

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

SHANGHAI, China and ST. HELIER, Jersey, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treatin…

Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role

Novocure Ltd. said Thursday Chief Science Officer Eilon Kirson will retire after about 7 years in the role, and 17 years with the company. The cancer treatment company said Kirson's retirement provides the opportunity to separate medical and scientific responsibilities. Uri Weinberg, vice president…
Show more

NovoCure Blogs

Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™

Optune Lua, formerly known as NovoTTF-100L, was approved by the FDA one year ago and is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer tr…

Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer

Final data collection will occur in six months ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver c…

Novocure to Report Second Quarter 2020 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial resu…

Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased l…

Novocure Reports First Quarter 2020 Financial Results and Provides Company Update

Quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019 Balance sheet strength allows continued investments in innovation and the advancement of commercial and development priorities ST. HELIER, Jersey…

Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I

EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial stud…
Show more

NovoCure Frequently Asked Questions

  • When was NovoCure founded?

    NovoCure was founded in 2000.

  • Who are NovoCure key executives?

    NovoCure's key executives are William F. Doyle, Asaf Danziger and William Burkoth.

  • How many employees does NovoCure have?

    NovoCure has 782 employees.

  • What is NovoCure revenue?

    Latest NovoCure annual revenue is $351.3 m.

  • What is NovoCure revenue per employee?

    Latest NovoCure revenue per employee is $449.3 k.

  • Who are NovoCure competitors?

    Competitors of NovoCure include PatientsLikeMe, Independa and HealthUnlocked.

  • Where is NovoCure headquarters?

    NovoCure headquarters is located at 13 Grenville St, Saint Helier.

  • Where are NovoCure offices?

    NovoCure has offices in Saint Helier, Atlanta, Boston, Charlotte and in 33 other locations.

  • How many offices does NovoCure have?

    NovoCure has 38 offices.